RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC36H40FN9O3

InChIKeyLCFFREMLXLZNHE-GBOLQPHISA-N

CAS Registry1575596-29-0

Clinical Trials associated with Rilzabrutinib

CTIS2026-525707-27-00

/ Not yet recruitingPhase 1

Study to assess the plasma concentration of rilzabrutinib given as a tablet to adult participants with severe renal impairment compared to matched participants with normal renal function

Start Date11 Sep 2026

Sponsor / Collaborator

Sanofi-Aventis Recherche & Développement SA

CTIS2026-525350-11-00

/ RecruitingPhase 1

A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants

Start Date30 Jun 2026

Sponsor / Collaborator

Sanofi-Aventis Recherche & Développement SA

NCT07007962

/ RecruitingPhase 3

A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-term extension period for selected participants (28 weeks) and a 24-week follow-up period only for eligible participants.

Start Date24 Oct 2025

Sponsor / Collaborator

Sanofi

100 Clinical Results associated with Rilzabrutinib

100 Translational Medicine associated with Rilzabrutinib

100 Patents (Medical) associated with Rilzabrutinib

Literatures (Medical) associated with Rilzabrutinib

03 Jul 2026·Expert Review of Hematology

Rilzabrutinib for persistent or chronic immune thrombocytopenia (ITP): a Bruton tyrosine kinase inhibitor that can target multiple pathophysiological pathways

Review

Author: Ghanima, Waleed ; Miyakawa, Yoshitaka ; Audia, Sylvain ; Mjali, Ahmed

INTRODUCTION:

Immune thrombocytopenia (ITP) is characterized by reduced platelet production and platelet destruction. Despite the availability of numerous treatments, many patients develop treatment resistance, experience relapse, or suffer from persistent symptoms such as fatigue, highlighting the need for innovative immune-modulating techniques. This review highlights the chemical properties, clinical efficacy and safety evidence for rilzabrutinib.

AREAS COVERED:

Bruton tyrosine kinase (BTK) is a promising therapeutic target in ITP as it is essential for B-cell receptor signaling, Fcγ receptor-mediated platelet clearance, and inflammatory amplification. Rilzabrutinib is a reversible, covalent oral BTK inhibitor developed to treat immune-mediated disorders. It targets several pathogenic immunological pathways. In the phase 2 LUNA 2 trial and the subsequent randomized, placebo-controlled, phase 3 LUNA 3 study, rilzabrutinib was clinically evaluated in patients with persistent or chronic ITP. The treatment resulted in durable platelet responses in extensively pretreated patients, decreased bleeding episodes, and led to significant improvements in patient-reported fatigue. The safety profile was generally good with adverse events considered mild to moderate.

EXPERT OPINION:

The approval of rilzabrutinib for persistent and chronic ITP represents an important addition to the therapeutic armamentarium for the disease. The drug's full potential will be further defined in future studies.

09 Jun 2026·JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY

A New Drug Target in Allergic Diseases: Bruton Tyrosine Kinase

Review

Author: Labrador-Horrillo, Moisés ; Cenni, Bruno ; Ferrer Puga, Marta

Though first recognized as a signaling molecule in B cells, Bruton tyrosine kinase (BTK) has been shown to play a crucial role in signal transduction in innate and adaptive immune cells. BTK is an attractive therapeutic target, given its diverse role in immune regulation. Development of the first-generation BTK inhibitor (BTKi), ibrutinib, revolutionized the treatment of B-cell malignancies. Since its approval, newer-generation BTKis with improved pharmacological properties have been developed, with higher selectivity for BTK and fewer off-target effects than ibrutinib. BTK is essential for IgE-driven allergic responses and may influence IgE antibody production by B cells. Activation of BTK via the high-affinity Fc receptor for IgE, FcεRI, results in mast cell and basophil degranulation and release of histamine and other inflammatory mediators. BTKis are a potential novel therapeutic option in patients with mast cell–driven autoimmune and allergic diseases. This review summarizes the current evidence for BTK in urticaria (chronic spontaneous and chronic inducible urticaria [CSU/CIndU]), asthma, food allergy, and atopic dermatitis (AD). It also highlights the efficacy of BTKis in urticaria and allergic diseases where FcεRI/IgE is the pathogenic target. Based on limited available data, BTK does not seem to have a prominent role in the pathogenesis of AD, and its role in asthma is unclear, thus necessitating further clinical research. Remibrutinib and rilzabrutinib have shown the most promise in allergic and autoimmune diseases to date; remibrutinib is approved in adults with CSU, and rilzabrutinib is approved in adults with persistent or chronic immune thrombocytopenia.

01 May 2026·PHARMACOLOGICAL RESEARCH

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders

Review

Author: Roskoski, Robert

The Bruton nonreceptor protein-tyrosine kinase (BTK) plays a central role in B cell antigen receptor signaling. Following B cell receptor activation, the Src protein kinase Lyn and the spleen protein kinase (Syk) activate BTK. It then mediates the phosphorylation and activation of phospholipase Cγ2 (PLCγ2). The Ras/RAF/MEK/ERK and NF-κB pathways are downstream of PLCγ2. These signaling modules participate in the affinity maturation of antibody-producing B cells by somatic hypermutation. The absence of BTK results in X-linked agammaglobulinemia. BTK contains an amino-terminal PH (pleckstrin homology) domain that interacts with phosphatidyl inositol trisphosphate within the plasma membrane to promote its membrane association. This is followed by a TEC homology segment, an SH3 and SH2 domain, and finally a carboxyterminal protein kinase domain. Aberrant B cell receptor signaling occurs in several B cell neoplasms including follicular lymphoma (treated with zanubrutinib, a BTK inhibitor), mantle cell lymphoma (acalabrutinib, pirtobrutinib, zanubrutinib), marginal zone lymphoma (zanubrutinib), chronic lymphocytic leukemia and small lymphocytic lymphoma (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib), and Waldenström macroglobulinemia (ibrutinib, zanubrutinib). Chronic spontaneous urticaria and chronic immune thrombocytopenia are driven by B cell dysfunction. The former is treated with remibrutinib and the latter is treated with rilzabrutinib, both of which inhibit BTK. Four drugs (ibrutinib, acalabrutinib, zanubrutinib, remibrutinib) form an irreversible covalent bond and rilzabrutinib forms a reversible covalent bond with BTK Cys481. Pirtobrutinib fails to form a covalent bond and is a reversible BTK inhibitor. The FDA-approvals of rilzabrutinib and remibrutinib (2025) represent the first nononcologic authorizations for BTK antagonists.

News (Medical) associated with Rilzabrutinib

23 Jun 2026

·www.biospace.com

Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia

Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, June 23, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization to Wayrilz (rilzabrutinib), a novel oral reversible Bruton’s tyrosine kinase inhibitor (BTKi), for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is considered to be problematic. Wayrilz can help address the underlying causes of the disease, through multi-immune modulation, targeting key pathways across the immune system. The approval is based on the LUNA 3 phase 3 study (clinical study identifier: NCT04562766) , in which Wayrilz met the primary and secondary endpoints, showing a positive impact on sustained platelet counts and other symptoms. "For ITP patients, achieving platelet counts close to normal and living without worrying about bleeding is extremely important. Additionally, in recent years, there has been growing interest in various other symptoms associated with ITP such as fatigue,” said Hisashi Kato , MD, PhD, Department of Blood Transfusion and Cell Therapy, The University of Osaka Hospital, Suita, Japan. “Wayrilz is a novel BTKi that works through multi-immune modulation to help address the root cause of ITP pathophysiology. It is expected to become a new therapeutic option that may help patients with disease management, including not only improvement in platelet counts but also considering patients' quality of life." “People living with immune thrombocytopenia who continue to experience symptoms, despite trying existing treatments, face a great unmet need,” said Manuela Buxo , Executive Vice President, Global Head of Specialty Care at Sanofi. “Wayrilz has a differentiated mechanism of action that enables multi-immune modulation to address the underlying pathophysiology of ITP and offers new hope to patients who have not responded to prior therapy. This milestone underscores Sanofi’s commitment to bringing innovative treatment options to rare disease patients around the world.” The LUNA 3 phase 3 study evaluated the efficacy and safety of Wayrilz compared to placebo in adults (n=202) with persistent or chronic ITP. Patients who achieved platelet count response at 12 weeks were eligible to continue the full 24-week double-blind period (64% of patients in the Wayrilz arm and 32% of patients in the placebo arm). Patients receiving Wayrilz experienced the following compared to patients receiving placebo: Statistically significant durable platelet response at week 25 (23% of patients in Wayrilz arm vs. 0% in placebo arm; p<0.0001) Faster time to first platelet response (36 days in Wayrilz arm vs. not reached in placebo arm; p<0.0001) Longer duration of platelet response (least square mean of 7 weeks in Wayrilz arm vs. 0.7 weeks in placebo arm) Patients receiving Wayrilz reported an overall 10.6-point improvement in the overall quality of life domain compared to a 2.3-point increase in the placebo arm, based on The Immune Thrombocytopenia Patient Assessment Questionnaire, a clinical tool designed to measure ITP symptoms and impacts. The results of this analysis are descriptive and were not powered for statistical significance. The most common adverse reactions (incidence ≥10%) were diarrhea, nausea, headache, abdominal pain, and COVID-19. Wayrilz is being studied across multiple other rare diseases, including IgG4-related disease (IgG4-RD), warm autoimmune hemolytic anemia (wAIHA), and sickle cell disease. These additional indications are currently under investigation and have not been approved by regulatory authorities. Japan has granted Wayrilz orphan drug designation for ITP, IgG4-RD, and wAIHA. About ITP ITP is a disease of complex immune dysregulation that causes low platelet counts (<100,000/μL), resulting in a variety of bleeding symptoms and high risk of thromboembolism. Beyond bruising and bleeding, which can include potentially life-threatening episodes like intracranial hemorrhage, people living with ITP may experience reduced quality of life, including physical fatigue and cognitive impairment. About Wayrilz Wayrilz (rilzabrutinib) is a novel oral reversible covalent BTK inhibitor that has the potential to be an effective new medicine for several rare immune-mediated or inflammatory diseases by working to restore immune balance via multi-immune modulation. The enzyme BTK, expressed in B cells, macrophages, and other innate immune cells, plays a critical role in multiple immune-mediated disease processes and inflammatory pathways. With the application of the TAILORED COVALENCY ® technology, Wayrilz can selectively inhibit the BTK target. Wayrilz is now approved for the treatment of ITP in the US, the EU, the UAE, the UK and Japan. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media Relations Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com Laura Romby | +33 6 74 16 74 29 | laura.romby@sanofi.com Investor Relations Thomas Kudsk Larsen |+44 7545 513 693 | thomas.larsen@sanofi.com Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com Sanofi Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” "attempt," “target,” “project,” "strategy," "strive," "desire," “predict,” “forecast,” “ambition,” “guideline,” "seek," “should,” “will,” "goal," or the negative of these and similar expressions are intended to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press_Release

Clinical ResultImmunotherapyPhase 3Drug ApprovalOrphan Drug

10 Jun 2026

·www.fiercebiotech.com

Ethyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s Tepezza

Ethyreal will share more information on its asset at the Endocrine Society’s 2026 Annual Meeting. \n Ethyreal Bio has exited stealth with $101 million in funding, joining the queue of companies preparing to challenge Amgen’s Tepezza.Backed by series A and B round investors, including Atlas Venture and Medicxi Ventures, the Massachusetts-based biotech has quietly advanced an anti-TSHR antibody to the cusp of clinical development. A first-in-human trial of the asset, dubbed ETHY-001, is scheduled to start this year. Ethyreal is developing the drug candidate for thyroid eye disease (TED) and Graves’ disease (GD).“These two conditions frequently coexist in the same individual, yet current treatments for GD do not treat or prevent TED, and conversely, TED treatments do not address the hyperthyroidism characteristic of GD,” Ethyreal CEO Niranjan Kameswaran, Ph.D., said in a statement.Amgen markets Tepezza in TED. With an FDA approval decision due this month, Viridian Therapeutics is at the front of a pack of companies aiming to compete with Amgen’s blockbuster. Tepezza and Viridian’s veligrotug both target IGF-1R. The GD pipeline includes argenx’s efgartigimod, Biohaven Therapeutics’ BHV-1300, Immunovant Sciences’ IMVT-1402 and Sanofi’s rilzabrutinib. Ethyreal has identified TSHR blockade as a way to treat TED and GD. By stopping autoantibodies from activating the receptor, the biotech aims to treat TED symptoms in the eye while tackling GD by reducing excess thyroid hormone production in thyroid cells.Other companies are pursuing similar approaches. Changchun GeneScience Pharmaceutical advanced an anti-TSHR antibody into the clinic and sold ex-China rights to the candidate to Yarrow Bioscience for $70 million upfront. Ollin Biosciences also entered the space by partnering with a Chinese biotech, agreeing to a financial package worth up to $440 million for rights to VelaVigo Bio’s TSHRxIGF-1R bispecific. The TSHR race includes oral antagonists. Crinetics Pharmaceuticals and Septerna have shared preclinical data on “nonpeptide” and small molecule TSHR antagonists, respectively, in recent years, although both biotechs are focused on other programs.Ethyreal will share more information on its contender next week at the Endocrine Society’s 2026 Annual Meeting. The presentation will cover preclinical data on an anti-TSHR antibody with half-life extension technology that is designed for subcutaneous administration using an autoinjector. Ethyreal has taken the asset toward the clinic using the proceeds of previously undisclosed series A and B rounds.

Drug ApprovalADC

01 Jun 2026

·www.fiercebiotech.com

Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study

Oscotec’s phase 2 trial missed its primary goal of demonstrating that cevidoplenib could double a patient’s platelet count after 12 weeks of treatment.\n Days after its lead clinical-stage drug suffered a setback, Agios Pharmaceuticals has rebounded by buying a blood disorder drug that flunked a phase 2 study.The prize is an oral spleen tyrosine kinase (SYK) inhibitor called cevidoplenib, which has been developed by Korea’s Oscotec. The biopharma has already taken cevidoplenib into a phase 2 study of 60 patients with a rare autoimmune blood disorder called immune thrombocytopenia (ITP).ITP affects around 200,000 people worldwide, including 90,000 in the U.S. alone, according to Agios. The condition is characterized by an immune system that destroys platelets, leading to an increased risk of bleeding.Oscotec’s phase 2 trial missed its primary goal of demonstrating that cevidoplenib could double a patient’s platelet count after 12 weeks of treatment. But Agios was undeterred, pointing to “durable and clinically meaningful platelet responses observed in the cevidoplenib arm compared with placebo across multiple secondary endpoints that align with primary endpoints used in ITP registrational trials.”Agios’ plan is to take the therapy into phase 3 trials in the first half of 2028, once it has completed additional chemistry, manufacturing, and controls (CMC) development work.Many patients with ITP receive steroids or thrombopoietin receptor agonists, such as Amgen’s Nplate or Novartis’ Promacta. Roche’s Rituxan is also used off-label to treat the condition in the U.S., though the antibody comes with some trade-offs when deployed against ITP. Meanwhile, Sanofi’s Wayrilz became the first BTK inhibitor to score an FDA approval for the clotting disease last year.Agios claimed that while current standard-of-care therapies are focused on increasing platelet counts and reducing bleeding risk, they are “often associated with limitations, including delayed onset of response, lack of durable efficacy, and class-specific adverse events, such as decreased blood counts and an increased risk of infections.”In return for the exclusive global rights to cevidoplenib, the Cambridge, Massachusetts-based biopharma is paying $25 million upfront and is liable for up to a further $140 million in development and regulatory milestones across up to three indications in the U.S. and Europe. If the drug secures an approval, Oscotec could also be in line for commercial milestone payments as well as royalties ranging from high single digit to mid-teens.Once the drug has cleared a phase 3 trial, Seongnam-based Oscotec has the option to secure the right to commercialize cevidoplenib on its home turf of South Korea.Cevidoplenib’s focus on ITP falls within Agios’ comfort zone of blood disorders. The biopharma’s sole commercial product is Pyrukynd, a PK activator that won approval in 2022 as the first therapy indicated for hemolytic anemia in adults with PK deficiency and has since expanded to treat anemia in adults with alpha- or beta-thalassemia under the brand name Aqvesme. Last week, Agio’s next-gen PK drug tebapivat failed a phase 2 study in lower-risk myelodysplastic syndromes, but the company is still persevering with the therapy in sickle cell disease.

Phase 2Drug ApprovalPhase 3Immunotherapy

100 Deals associated with Rilzabrutinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11873	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Purpura, Thrombocytopenic, Idiopathic	United Arab Emirates	Sanofi	08 Jul 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Immunoglobulin G4-Related Disease	Phase 3	United States	Sanofi	26 Sep 2025
Immunoglobulin G4-Related Disease	Phase 3	China	Sanofi	26 Sep 2025
Immunoglobulin G4-Related Disease	Phase 3	Japan	Sanofi	26 Sep 2025
Immunoglobulin G4-Related Disease	Phase 3	Argentina	Sanofi	26 Sep 2025
Immunoglobulin G4-Related Disease	Phase 3	Belgium	Sanofi	26 Sep 2025
Immunoglobulin G4-Related Disease	Phase 3	Canada	Sanofi	26 Sep 2025
Immunoglobulin G4-Related Disease	Phase 3	Chile	Sanofi	26 Sep 2025
Immunoglobulin G4-Related Disease	Phase 3	France	Sanofi	26 Sep 2025
Immunoglobulin G4-Related Disease	Phase 3	Germany	Sanofi	26 Sep 2025
Immunoglobulin G4-Related Disease	Phase 3	Israel	Sanofi	26 Sep 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05018806 (CTgov)	Phase 2	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	124	Placebo (BID Cohort: Placebo)	ooruqgrlao(qurkeyhleg) = vuyhtfrouc grbxansfwn (cdvlhqzxes, 9.77) View more	-	13 Jul 2026
				Rilzabrutinib (BID Cohort: Rilzabrutinib)	ooruqgrlao(qurkeyhleg) = mhtrpjyjmu grbxansfwn (cdvlhqzxes, 8.25) View more
NCT04562766 (LUNA3, EHA2026)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	69	Rilzabrutinib 400 mg bid	okgmewoehi(adafoxdgiy) = spzbzdnkyz xxmxvrgeun (ggahuegfsj ) View more	Positive	12 May 2026
NCT05104892 (Pubmed \| Lancet Respir Med)	Phase 2	-	196	Rilzabrutinib 800 mg per day	cxvrdoqrwl(ytraqfcmyc) = ylbwbuwtlu tatadakfwu (qdxpbimrvh )	Negative	01 Apr 2026
				Placebo	cxvrdoqrwl(ytraqfcmyc) = dxgioibecv tatadakfwu (qdxpbimrvh )
NCT04562766 (LUNA3 \| LUNA 3, CTgov)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	232	placebo+rilzabrutinib (DB Period: Adults: Placebo)	ynrmbndceb = qamfhekgbv xndjlcecbk (jkiykkuccd, arsneanafl - bsobdxzzsa) View more	-	23 Feb 2026
				Rilzabrutinib (DB Period: Adults: Rilzabrutinib 400 mg BID)	ynrmbndceb = updhixktyl xndjlcecbk (jkiykkuccd, zuqoekeqwq - gngrwllddk) View more
NCT06975865 (LIBRA, ASH2025)	Phase 3	Anemia, Sickle Cell	192	Rilzabrutinib	afapctoreu(rxclxuacjg) = oparcqfliq mogilyvcjy (cccfxzamwy )	Positive	06 Dec 2025
				Placebo	afapctoreu(rxclxuacjg) = eudyfoiuac mogilyvcjy (cccfxzamwy )
LUMINA2 part B (ASH2025)	Phase 2	Warm autoimmune hemolytic anemia	15	Rilzabrutinib	cdqninrolb(gnlwcqfvcq) = ytpquvemoq dihknrsico (gmcnpftgky ) View more	Positive	06 Dec 2025
NCT04562766 (LUNA3, ASH2025)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	180	Rilzabrutinib 400 mg bid	yghgdcjkan(qlrlhfzhgx) = zfuemwpljy paynzdjxie (aoknyczvaw ) View more	Positive	06 Dec 2025
				Placebo	cxerdmfaho(hgytjgweyg) = scsfewgmri llnxfoqdfv (mvmjmollpq ) View more
NCT04562766 (LUNA3, ASH2025)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	202	Rilzabrutinib	bfplfebyqs(frimkmnvuf) = Two pts (3%) had grade ≥2 related TEAE of infection exkkwszxse (xipthvyvgo ) View more	Positive	06 Dec 2025
				Rilzabrutinib
NCT04520451 (ACR2025)	Phase 2	Immunoglobulin G4-Related Disease	27	Rilzabrutinib	asnobljfjp(hlpznrehmh) = rhhofgmcos liipuwdtnc (skjlybufnl ) View more	Positive	24 Oct 2025
NCT05104892 (Phase 2 Study, ATS2025)	Phase 2	Asthma	196	Rilzabrutinib 800mg	ipxcnynqta(qiytjetiyk) = rajxjdbcoo mpqisnpcyn (gmyksietfq )	Positive	16 May 2025
				Placebo	ipxcnynqta(qiytjetiyk) = htyaoihceg mpqisnpcyn (gmyksietfq )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis